Axogen, Inc. (AXGN)
| Market Cap | 2.39B |
| Revenue (ttm) | 238.11M |
| Net Income (ttm) | -31.45M |
| Shares Out | 53.18M |
| EPS (ttm) | -0.67 |
| PE Ratio | n/a |
| Forward PE | 74.46 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,229,845 |
| Open | 44.41 |
| Previous Close | 44.49 |
| Day's Range | 43.52 - 45.19 |
| 52-Week Range | 10.14 - 46.00 |
| Beta | 1.12 |
| Analysts | Strong Buy |
| Price Target | 50.78 (+13.02%) |
| Earnings Date | Aug 4, 2026 |
About AXGN
Axogen, Inc., together with its subsidiaries, engages in the development and commercialization of the technologies used for peripheral nerve regeneration and repair worldwide. The company offers Avance Nerve Graft, a processed nerve allograft intended for the surgical repair of peripheral nerve discontinuities; Axoguard Nerve Connector, a coaptation aid used to align and connect severed peripheral nerve ends in a tensionless repair; and Axoguard Nerve Protector, a product used to protect and wrap damaged peripheral nerves and reinforce reconstr... [Read more]
Financial Performance
In 2025, Axogen's revenue was $225.21 million, an increase of 20.21% compared to the previous year's $187.34 million. Losses were -$15.70 million, 57.6% more than in 2024.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for AXGN stock is "Strong Buy." The 12-month stock price target is $50.78, which is an increase of 13.02% from the latest price.
News
Axogen Transcript: AGM 2026
The meeting was held virtually, with all director nominees elected, auditor ratified, and executive compensation approved by large majorities. Shareholders had opportunities for questions, and final voting results will be filed in a Form 8-K.
Axogen Transcript: Bank of America Global Healthcare Conference 2026
Management outlined a unified strategic plan focused on peripheral nerve repair, highlighted recent reimbursement wins, and discussed ongoing payer negotiations. Financial guidance remains strong, with operational improvements expected to boost margins, and new clinical data may drive future growth.
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
ALACHUA, Fla. and TAMPA, Fla.
AxoGen price target raised to $48 from $41 at Raymond James
Raymond James raised the firm’s price target on AxoGen (AXGN) to $48 from $41 and keeps an Outperform rating on the shares. Axogen is delivering its strongest growth in five…
AxoGen price target raised to $50 from $45 at Canaccord
Canaccord analyst Caitlin Roberts raised the firm’s price target on AxoGen (AXGN) to $50 from $45 and keeps a Buy rating on the shares. The firm said they posted an…
Axogen Proxy statement: Proxy filing
Axogen filed a proxy statement on April 29, 2026, providing details for shareholder voting and corporate governance matters.
AxoGen price target raised to $50 from $39 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on AxoGen (AXGN) to $50 from $39 and keeps a Buy rating on the shares following the Q1 sales beat. AxoGen is an…
AxoGen price target raised to $50 from $42 at Citizens
Citizens raised the firm’s price target on AxoGen (AXGN) to $50 from $42 and keeps an Outperform rating on the shares. The bullish view on AxoGen is driven by its…
Axogen Earnings Call Transcript: Q1 2026
Revenue grew 26.6% year-over-year to $61.5M in Q1 2026, with strong double-digit growth across all markets and expanded commercial coverage. Full-year guidance was raised to at least $270M revenue and 74%-76% gross margin, with continued investment in sales force and innovation.
Axogen Earnings release: Q1 2026
Axogen released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Axogen Slides: Q1 2026
Axogen has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on April 28, 2026.
Axogen Quarterly report: Q1 2026
Axogen has published its Q1 2026 quarterly earnings report on April 28, 2026.
AxoGen raises FY26 revenue view to $270M from $265.7M, consensus $265.89M
The company said, “We expect 2026 revenue growth to be at least 20%, or $270 million, for the full-year and gross margin to be in the range of 74% to…
AxoGen reports Q1 adjusted EPS 7c, consensus 7c
Reports Q1 revenue $61.46M, consensus $57.77M. “We are pleased with our first-quarter revenue performance and the progress we’re making across each of Axogen’s (AXGN) strategic plan priorities,” said ...
Axogen, Inc. Reports First Quarter 2026 Financial Results
ALACHUA, Fla. and TAMPA, Fla.
AxoGen price target raised to $45 from $40 at Canaccord
Canaccord raised the firm’s price target on AxoGen (AXGN) to $45 from $40 and keeps a Buy rating on the shares. The firm updated its model heading ito Q1 results.
AxoGen price target raised to $50 from $40 at Lake Street
Lake Street raised the firm’s price target on AxoGen (AXGN) to $50 from $40 and keeps a Buy rating on the shares. Anthem and Cigna recently issued positive coverage policies…
AxoGen jumps after Cigna picks up Avance nerve graft
Shares of AxoGen (AXGN) moved higher after Cigna (CI) added coverage for the company’s nerve graft. AxoGen’s Avance Nerve Graft “is considered medically necessary when used in association with mastect...
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
ALACHUA, Fla. and TAMPA, Fla.
Axogen Transcript: The Citizens Life Sciences Conference 2026
Achieved broad BLA label and 12 years of exclusivity, enabling continued market leadership in nerve care. Insurance coverage is expanding, with all technical requirements met for major payers, and CMS reimbursement has improved. Growth strategies focus on education, targeted accounts, and expanding the sales force.
Axogen Transcript: Leerink Global Healthcare Conference 2026
Validated business models and double-digit growth across all segments are driving expansion, with a strengthened balance sheet and at least 18% top-line growth targeted for 2026. Regulatory milestones and reimbursement wins set the stage for operational efficiencies and broader market access.
Axogen Slides: Corporate presentation
Axogen has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Axogen Transcript: 47th Annual Raymond James Institutional Investor Conference
Focused on making peripheral nerve restoration a standard of care, the company targets growth in extremities, breast, and oral maxillofacial markets, with prostate care in development. Recent BLA approval for AVANCE supports payer coverage and operational improvements, while strong financials and a recent capital raise position the company for continued expansion.
Axogen Earnings Call Transcript: Q4 2025
Revenue grew 20% year-over-year with strong double-digit growth across all markets and a key FDA BLA approval for Avance. 2026 guidance targets at least 18% revenue growth, with gross margin stability and continued investment in commercial and R&D initiatives.